Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D S, Sonnichsen"'
Publikováno v:
Cancer Chemotherapy and Pharmacology. 43:221-226
Purpose: This study was undertaken to address the influence of concurrent administration on the pharmacokinetics of UFT (uracil plus tegafur) and leucovorin (LV), and to measure the antitumor activity of a 28-consecutive-day oral regimen of UFT plus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b3ddb644c6d86ae2fab4892345f4e71
https://doi.org/10.1007/s002800050887
https://doi.org/10.1007/s002800050887
Autor:
M H, Woo, M V, Relling, D S, Sonnichsen, G K, Rivera, C B, Pratt, C H, Pui, W E, Evans, A S, Pappo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(3)
Clearance of anticancer drugs in children is highly variable, leading to wide variability in the systemic exposure associated with each dosage escalation in Phase I studies. The purpose of this Phase I study was to escalate targeted systemic exposure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f53e862d98cb010dd09b901cafc081dd
https://pubmed.ncbi.nlm.nih.gov/10100705
https://pubmed.ncbi.nlm.nih.gov/10100705
Autor:
N F, Ford, D S, Sonnichsen
Publikováno v:
Pharmacotherapy. 18(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cfc7668c38fa1be33a344cad1fd604e9
https://pubmed.ncbi.nlm.nih.gov/9469685
https://pubmed.ncbi.nlm.nih.gov/9469685
Publikováno v:
Oncology (Williston Park, N.Y.). 11(9 Suppl 10)
Therapeutic options for patients with advanced colorectal cancer who have failed treatment with fluorouracil (5-FU) are limited. Responses have been reported in this setting with a protracted venous infusion of 5-FU. Daily oral therapy with tegafur a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a48149800f8b6d40cf05674291c04d67
https://pubmed.ncbi.nlm.nih.gov/9348562
https://pubmed.ncbi.nlm.nih.gov/9348562
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 275(2)
Formation of 6 alpha-hydroxypaclitaxel has been described as the primary biotransformation pathway for paclitaxel in vitro and in vivo, with additional formation of two other "minor" metabolites. Using a large group (n = 49) of human liver microsomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c4ae7c1dbd8badc82cc9a8313fb15dd2
https://pubmed.ncbi.nlm.nih.gov/7473140
https://pubmed.ncbi.nlm.nih.gov/7473140